![Associate Professor Fernando Guimaraes](/sites/default/files/profiles/9730.jpeg)
Overview
Background
I lead a research program with extensive expertise in immunology, particularly in natural killer (NK) cells, focused on developing innovative approaches for treating hard-to-cure diseases like metastatic cancers. Our mission is to improve patient outcomes and extend lives. My research group is based at the Translational Research Institute (TRI).
My dedication to my field has been recognized through numerous peer-reviwed grants as sole-CI or CIA/Principal Investigator, including a NHMRC ECF Peter Doherty Fellowship, an NHMRC Project Grant, an US DoD, a MRFF EMCR among others. Since 2009, I've amassed an impressive portfolio of 96 publications in renowned journals like Blood, Cell Death Dis, JEM, PNAS, Nat Comms, and Nat Immunol with an H-index = 40. My body of work and contributions have been acknowledged with awards such as the 2019 Researcher of the Year by CCA, 2020 QLD Young Tall Poppy Science, 2020 UQ Frazer Institute's Rising Star, 2022 Frazer Institute's Mentor of the Year, 2023 Translational Research Institute - Connecting with the Clinic among others. Recognized as an international leader in my field, I've been instrumental in identifying novel regulators of our immune functions, and developing NK cell-based immunotherapies.
At present, I am a Group Leader / Principal Research Fellow & Associate Professor with the University of Queensland's Frazer Institute. Here, I lead a high-performing research team with a keen focus on developing and innovating immunotherapy approaches for a spectrum of diseases.
Availability
- Associate Professor Fernando Guimaraes is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Doctor of Philosophy, unknown
Research interests
-
NK cells
Overview: Natural Killer (NK) cells are a crucial component of the innate immune system, recognized for their ability to target and destroy cancerous or infected cells without prior sensitization. Their unique capability to distinguish between healthy and abnormal cells makes them pivotal in immunological defenses and cancer immunosurveillance. Current research: My current research focuses on unraveling the complex interactions of NK cells within various disease environments. We are investigating how NK cells respond to different cancer types, particularly in the context of hard-to-cure solid cancers (e.g. pediatric sarcomas). Our recent findings suggest novel pathways through which NK cells can be modulated to enhance their cytotoxicity against tumor cells. We are also exploring the impact of the tumor microenvironment on NK cell function, hypothesizing that certain microenvironmental factors might inhibit their activity and how this can be counteracted. Future directions: Looking forward, our goal is to develop strategies to boost NK cell efficacy in cancer therapy. This includes genetic engineering of NK cells to enhance their tumor-targeting capabilities and the identification of new biomarkers for predicting patient response to NK cell-based therapies. Our ultimate aim is to leverage NK cells' natural abilities to create more effective and less toxic cancer treatments.
-
Systems immunology and checkpoint discovery
Explanation of systems immunology: Systems immunology integrates computational and experimental approaches to understand the immune system's complexity. By analyzing vast datasets, we can decipher the intricate network of cellular interactions and molecular pathways that govern immune responses in diseases ranging from viral infections to cancer. Immunomodulation and disease environments: Our research in systems immunology focuses on understanding how immunomodulation varies across different disease states. We are particularly interested in how immune checkpoints, which are regulatory pathways crucial to maintaining self-tolerance and preventing autoimmunity, can be exploited or inhibited in disease contexts. For instance, we are exploring how tumor cells evade immune surveillance by manipulating these checkpoints. Impact of Research: This research holds significant promise for unveiling new therapeutic targets and developing personalized medicine approaches. Understanding these complex immune interactions can lead to the discovery of novel treatments that precisely modulate the immune system to combat various diseases effectively.
-
Development of tailored immunotherapies
Introduction to tailored immunotherapies: Tailored immunotherapies represent a revolutionary approach in medicine, offering treatments that are specifically designed to match an individual's unique immune profile. This personalized approach is particularly crucial in treating hard-to-cure diseases, where standard therapies often fall short. From antibody discovery to development: My team is actively engaged in the discovery and development of novel antibodies. We focus on identifying antibodies that can specifically target and modulate key components of the immune system. The journey from discovery to development involves extensive research to ensure efficacy and safety, with a keen focus on creating therapies that can be personalized for individual patients. Cellular immunotherapies: Our work in cellular immunotherapies involves engineering immune cells, such as T-cells and NK cells, to better recognize and attack cancer cells. We are exploring various techniques, including CAR-NK cell therapy, to enhance these cells' ability to fight cancer more effectively. Real-world applications: The potential real-world applications of our research are vast. For example, our work in antibody development could lead to new treatments for autoimmune diseases or cancer. Similarly, our advancements in cellular therapies could revolutionize the way we treat various forms of cancer, offering hope to patients with previously untreatable conditions.
Works
Search Professor Fernando Guimaraes’s works on UQ eSpace
2024
Journal Article
The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment
Farrell, Luke A., O’Rourke, Matthew B., Padula, Matthew P., Souza-Fonseca-Guimaraes, Fernando, Caramori, Gaetano, Wark, Peter A. B., Dharmage, Shymali C. and Hansbro, Phillip M. (2024). The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment. Proteomes, 12 (3), 23. doi: 10.3390/proteomes12030023
2024
Conference Publication
Trastuzumab-Induced Cardiotoxicity Involves Antibody Dependent Cell Cytotoxicity (ADCC)
Griffiths, L., Ho, U., Burt, K., Watson, S., Patel, K., Bradford, J., Tan, C., Bhavsar, C., Palpant, N., Souza-Fonseca-Guimaraes, F., Wu, S., Reichelt, M. and Thomas, W. (2024). Trastuzumab-Induced Cardiotoxicity Involves Antibody Dependent Cell Cytotoxicity (ADCC). 72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Perth, WA Australia, 1-4 August 2024. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2024.06.397
2024
Journal Article
The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy
McCulloch, Timothy R, Rossi, Gustavo R, Miranda‐Hernandez, Socorro, Valencia‐Hernandez, Ana Maria, Alim, Louisa, Belle, Clemence J, Krause, Andrew, Zacchi, Lucia F, Lam, Pui Yeng, Nakamura, Kyohei, Kupz, Andreas, Wells, Timothy J and Souza‐Fonseca‐Guimaraes, Fernando (2024). The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy. Immunology & Cell Biology. doi: 10.1111/imcb.12794
2024
Journal Article
TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer
Wong, Joshua K.M., McCulloch, Timothy R., Alim, Louisa, Omer, Natacha, Mehdi, Ahmed M., Tuong, Zewen Kelvin, Bonfim-Melo, Alexis, Chung, Eric, Nicol, Alice, Simpson, Fiona, Rhee, Handoo, Rossi, Gustavo Rodrigues and Souza-Fonseca-Guimaraes, Fernando (2024). TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. eBioMedicine, 104 105176, 105176. doi: 10.1016/j.ebiom.2024.105176
2024
Journal Article
Highlight of 2023: Unlocking the therapeutic potential of <scp>natural killer</scp> cells—advances in adaptive functions, cellular engineering and immunotherapy
Lam, Pui Yeng and Souza‐Fonseca‐Guimaraes, Fernando (2024). Highlight of 2023: Unlocking the therapeutic potential of natural killer cells—advances in adaptive functions, cellular engineering and immunotherapy. Immunology & Cell Biology, 102 (6), 444-447. doi: 10.1111/imcb.12769
2024
Journal Article
Correction to: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells (Nature Immunology, (2017), 18, 9, (1004-1015), 10.1038/ni.3800)
Gao, Yulong, Souza-Fonseca-Guimaraes, Fernando, Bald, Tobias, Ng, Susanna S., Young, Arabella, Ngiow, Shin Foong, Rautela, Jai, Straube, Jasmin, Waddell, Nic, Blake, Stephen J., Yan, Juming, Bartholin, Laurent, Lee, Jason S., Vivier, Eric, Takeda, Kazuyoshi, Messaoudene, Meriem, Zitvogel, Laurence, Teng, Michele W. L., Belz, Gabrielle T., Engwerda, Christian R., Huntington, Nicholas D., Nakamura, Kyohei, Hölzel, Michael and Smyth, Mark J. (2024). Correction to: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells (Nature Immunology, (2017), 18, 9, (1004-1015), 10.1038/ni.3800). Nature Immunology, 25 (5), 925-926. doi: 10.1038/s41590-024-01799-9
2024
Conference Publication
Spatial profiling of pediatric rhabdomyosarcoma to elucidate their immunosuppressive tumor microenvironment
Tu, Cui, Tan, Chin Wee, Liu, Ning, Kulasinghe, Arutha and Souza-Fonseca-Guimaraes, Fernando (2024). Spatial profiling of pediatric rhabdomyosarcoma to elucidate their immunosuppressive tumor microenvironment. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-73
2024
Journal Article
In situ single-cell profiling sheds light on IFI27 localisation during SARS-CoV-2 infection
Tan, Chin Wee, Chen, Jinjin, Liu, Ning, Bhuva, Dharmesh D., Blick, Tony, Monkman, James, Cooper, Caroline, Kharbanda, Malvika, Feher, Kristen, Phipson, Belinda, Killingbeck, Emily E., Pan, Liuliu, Kim, Youngmi, Liang, Yan, Nam, Andy, Leon, Michael, Souza-Fonseca-Guimaraes, Paulo, Nagashima, Seigo, Camargo Martins, Ana Paula, Machado-Souza, Cleber, de Noronha, Lucia, Tang, Benjamin, Short, Kirsty, Fraser, John, Belz, Gabrielle T., Souza-Fonseca-Guimaraes, Fernando, Kulasinghe, Arutha and Davis, Melissa J. (2024). In situ single-cell profiling sheds light on IFI27 localisation during SARS-CoV-2 infection. eBioMedicine, 101 105016, 1-4. doi: 10.1016/j.ebiom.2024.105016
2024
Journal Article
Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches: Position paper
Welsh, Joshua A., Goberdhan, Deborah C. I., O'Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A. P., Erdbrugger, Uta, Falcon-Perez, Juan M., Fu, Qing-Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, Mahoney, My G., Mohanty, Sujata, Moller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco ... Allenby, Mark (2024). Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches: Position paper. Journal of Extracellular Vesicles, 13 (2) e12404. doi: 10.1002/jev2.12404
2024
Journal Article
Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment
Alim, Louisa F, Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2024). Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Current Opinion in Immunology, 86 102409, 102409. doi: 10.1016/j.coi.2023.102409
2024
Journal Article
IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development
Goh, Wilford, Sudholz, Harrison, Foroutan, Momeneh, Scheer, Sebastian, Pfefferle, Aline, Delconte, Rebecca B., Meng, Xiangpeng, Shen, Zihan, Hennessey, Robert, Kong, Isabella Y., Schuster, Iona S., Andoniou, Christopher E., Davis, Melissa J., Hediyeh-Zadeh, Soroor, Souza-Fonseca-Guimaraes, Fernando, Parish, Ian A., Beavis, Paul, Thiele, Daniel, Chopin, Michael, Degli-Esposti, Mariapia A., Cursons, Joe, Kallies, Axel, Rautela, Jai, Nutt, Stephen L. and Huntington, Nicholas D. (2024). IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development. Nature Immunology, 25 (2), 240-255. doi: 10.1038/s41590-023-01718-4
2024
Journal Article
Leveraging spatial omics for the development of precision sarcoma treatments
Tu, Cui, Kulasinghe, Arutha, Barbour, Andrew and Souza-Fonseca-Guimaraes, Fernando (2024). Leveraging spatial omics for the development of precision sarcoma treatments. Trends in Pharmacological Sciences, 45 (2), 134-144. doi: 10.1016/j.tips.2023.12.006
2024
Journal Article
Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis
Tu, Cui, Buckle, Irina, Leal Rojas, Ingrid, Rossi, Gustavo Rodrigues, Sester, David P, Moore, Andrew S, Radford, Kristen, Guillerey, Camille and Souza‐Fonseca‐Guimaraes, Fernando (2024). Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis. Clinical & Translational Immunology, 13 (3) e1501, e1501. doi: 10.1002/cti2.1501
2024
Journal Article
Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signatures
Stylianou, Nataly, Sebina, Ismail, Matigian, Nicholas, Monkman, James, Doehler, Hadeel, Röhl, Joan, Allenby, Mark, Nam, Andy, Pan, Liuliu, Rockstroh, Anja, Sadeghirad, Habib, Chung, Kimberly, Sobanski, Thais, O'Byrne, Ken, Almeida, Ana Clara Simoes Florido, Rebutini, Patricia Zadorosnei, Machado‐Souza, Cleber, Stonoga, Emanuele Therezinha Schueda, Warkiani, Majid E, Salomon, Carlos, Short, Kirsty, McClements, Lana, de Noronha, Lucia, Huang, Ruby, Belz, Gabrielle T, Souza‐Fonseca‐Guimaraes, Fernando, Clifton, Vicki and Kulasinghe, Arutha (2024). Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signatures. Clinical & Translational Immunology, 13 (2) e1488, e1488. doi: 10.1002/cti2.1488
2023
Journal Article
Development of physiologically relevant skin organoids from human induced pluripotent stem cells
Shafiee, Abbas, Sun, Jane, Ahmed, Imaan A., Phua, Felicia, Rossi, Gustavo R., Lin, Cheng‐Yu, Souza‐Fonseca‐Guimaraes, Fernando, Wolvetang, Ernst J., Brown, Jason and Khosrotehrani, Kiarash (2023). Development of physiologically relevant skin organoids from human induced pluripotent stem cells. Small, 20 (16) e2304879, 1-14. doi: 10.1002/smll.202304879
2023
Journal Article
A robust platform for integrative spatial multi‐omics analysis to map immune responses to SARS‐CoV‐2 infection in lung tissues
Tan, Xiao, Grice, Laura F., Tran, Minh, Mulay, Onkar, Monkman, James, Blick, Tony, Vo, Tuan, Almeida, Ana Clara, da Silva Motta, Jarbas, Fernandes de Moura, Karen, Machado‐Souza, Cleber, Souza‐Fonseca‐Guimaraes, Paulo, Baena, Cristina Pellegrino, de Noronha, Lucia, Guimaraes, Fernanda Simoes Fortes, Luu, Hung N., Drennon, Tingsheng, Williams, Stephen, Stern, Jacob, Uytingco, Cedric, Pan, Liuliu, Nam, Andy, Cooper, Caroline, Short, Kirsty, Belz, Gabrielle T., Souza‐Fonseca‐Guimaraes, Fernando, Kulasinghe, Arutha and Nguyen, Quan (2023). A robust platform for integrative spatial multi‐omics analysis to map immune responses to SARS‐CoV‐2 infection in lung tissues. Immunology, 170 (3), 401-418. doi: 10.1111/imm.13679
2023
Journal Article
Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer
Poursani, Ensieh M., Mercatelli, Daniele, Raninga, Prahlad, Bell, Jessica L., Saletta, Federica, Kohane, Felix V., Neumann, Daniel P., Zheng, Ye, Rouaen, Jourdin R. C., Jue, Toni Rose, Michniewicz, Filip T., Schadel, Piper, Kasiou, Erin, Tsoli, Maria, Cirillo, Giuseppe, Waters, Shafagh, Shai-Hee, Tyler, Cazzoli, Riccardo, Brettle, Merryn, Slapetova, Iveta, Kasherman, Maria, Whan, Renee, Souza-Fonseca-Guimaraes, Fernando, Vahdat, Linda, Ziegler, David, Lock, John G., Giorgi, Federico M., Khanna, KumKum and Vittorio, Orazio (2023). Copper chelation suppresses epithelial-mesenchymal transition by inhibition of canonical and non-canonical TGF-β signaling pathways in cancer. Cell and Bioscience, 13 (1) 132, 132. doi: 10.1186/s13578-023-01083-7
2023
Journal Article
Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2
McCulloch, Timothy R., Rossi, Gustavo Rodrigues, Lam, Allie, Wong, Joshua, Kane, Lawrence P, Herold, Marco, Wells, Timothy and Souza-Fonseca-Guimaraes, Fernando (2023). Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2. The Journal of Immunology, 210 (S1), 72.28-72.28. doi: 10.4049/jimmunol.210.supp.72.28
2023
Conference Publication
TIGIT limits anti-bacterial immunity and is a potential target for immunotherapy
Souza-Fonseca-Guimaraes, Fernando, Rossi, Gustavo Rodrigues, Wells, Timothy and McCulloch, Timothy Ryan (2023). TIGIT limits anti-bacterial immunity and is a potential target for immunotherapy. IMMUNOLOGY2023™ Meeting, Washington, DC, United States, 11 - 15 May 2023. Rockville, MD, United States: The American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.64.14
2023
Journal Article
Oncogenic drivers dictate immune control of acute myeloid leukemia
Austin, Rebecca J., Straube, Jasmin, Halder, Rohit, Janardhanan, Yashaswini, Bruedigam, Claudia, Witkowski, Matthew, Cooper, Leanne, Porter, Amy, Braun, Matthias, Souza-Fonseca-Guimaraes, Fernando, Minnie, Simone A., Cooper, Emily, Jacquelin, Sebastien, Song, Axia, Bald, Tobias, Nakamura, Kyohei, Hill, Geoffrey R., Aifantis, Iannis, Lane, Steven W. and Bywater, Megan J. (2023). Oncogenic drivers dictate immune control of acute myeloid leukemia. Nature Communications, 14 (1) 2155, 1-14. doi: 10.1038/s41467-023-37592-9
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Fernando Guimaraes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Which tumour immunosuppressive pathways prevent natural killer cell activation?
Background: Despite advances in treatment and earlier detection, cancer is still a main cause of cancer death worldwide. Natural killer (NK) cells are circulating innate lymphocytes that naturally protect against tumor spread (metastasis), and recently showed by our group as dysfunctional in the tumour microenvironment (TME) established by cancers at distant organs for future metastatic spread. Yet, despite knowing that NK cells do control cancer metastasis, our knowledge of how cancer cells evade NK cell control is still very poor. This project aims to examine several immune suppressive pathways that cancers likely manipulate to avoid NK cells and spread. These include factors the transforming growth factor (TGF)-β superfamily that are elevated in the tumor environment. These molecules have great potential to suppress the normally high killing and anti-metastatic activity mediated by NK cells, but to date we still need to elucidate how relatively important each pathway might be.
Proposed research program: The intrinsic NK cell function under suppressive factors stimulation will be assessed with NK cells purified from mouse spleen (wild type) by cell sorter, and in vitro challenge with activating cytokines and suppressive factors. Aim-1: Which suppressive factor is a major inhibitor of NK cell killing activity? This aim will be screened by killing activity of NK cells versus target tumour cells in co-culture systems. Aim-2: Which suppressive factor is a major inhibitor of NK cell cytokine secretion? This aim will assess NK cell cytokine production by intracellular cytokine (e.g. IFN-gamma) staining (flow cytometry) and secreted IFN-gamma, among others, from culture supernatants (ELISA); Aim-3: What is the cellular signalling status under suppressive conditions? The identification of altered cellular signalling will be screened by intracellular staining of phosphorylated signalling molecules (phosphor(p)-AKT, p-ERK1/2, p-p38, p-phospholipase C-gamma2, p-phosphotyrosine, p-SMAD2,3, p-STAT4, p-STAT5 and p-ZAP70 (PhosphoFlow).
These experimental tools will determine which is the most important suppressive pathway in inhibiting NK cell functions. Information we obtain from this work will allow us to design rationale approaches to increase NK cell function in personalised immunotherapy approaches.
Supervision history
Current supervision
-
Doctor Philosophy
KIR-mismatched NK-cells graft-versus-paediatric sarcoma effect
Principal Advisor
Other advisors: Dr Gustavo Rodrigues Rossi, Associate Professor Wayne Nicholls
-
Doctor Philosophy
Enhancement of natural killer cell function for therapeutic targeting and elimination of metastatic breast cancer
Principal Advisor
Other advisors: Associate Professor Fiona Simpson, Dr Gustavo Rodrigues Rossi
-
Master Philosophy
Spatial multi-omics to study hard-to-cure lung infections
Principal Advisor
Other advisors: Dr Ahmed Mehdi, Dr Arutha Kulasinghe
-
Doctor Philosophy
Harnessing the power of iPSC-NK cells for cancer immunotherapy
Principal Advisor
Other advisors: Associate Professor Fiona Simpson, Dr Mathew Jones, Associate Professor Andrew Brooks
-
Doctor Philosophy
Reversing tumour necrosis factor-mediated immunosuppression to boost immunity against experimental CD19+ blood cancers
Principal Advisor
Other advisors: Associate Professor Colm Keane, Dr Allie Lam
-
Doctor Philosophy
Immune regulation through bi-directional interactions between subsets of Natural Killer cells and Dendritic cells.
Principal Advisor
Other advisors: Professor Andrew Barbour, Dr Arutha Kulasinghe, Dr Camille Guillerey, Dr Gustavo Rodrigues Rossi
-
Doctor Philosophy
Development of natural killer cells with enhanced tumoricidal functions using CRISPR homology-directed repair-mediated gene editing
Principal Advisor
Other advisors: Professor Gabrielle Belz, Dr Allie Lam
-
Doctor Philosophy
Utilising alternative cytokine receptor signalling for enhanced cell-based cancer immunotherapy.
Associate Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law, Associate Professor Andrew Brooks
-
Doctor Philosophy
Understanding key epithelial cells in lung infections
Associate Advisor
Other advisors: Professor Gabrielle Belz
-
Doctor Philosophy
Characterising cytotoxic T cell fates in allogeneic stem cell transplantation
Associate Advisor
Other advisors: Dr Arutha Kulasinghe
-
Doctor Philosophy
Investigation of immune responses to novel and standard therapies in DLBCL
Associate Advisor
Other advisors: Dr Joshua Tobin, Associate Professor Colm Keane
-
Doctor Philosophy
The role of innate cells in shaping the tumour environment.
Associate Advisor
Other advisors: Professor Gabrielle Belz
Completed supervision
-
2023
Doctor Philosophy
Investigating immunosuppression and immunotherapy in bacterial infection
Principal Advisor
Other advisors: Dr Timothy Wells
-
Media
Enquiries
Contact Associate Professor Fernando Guimaraes directly for media enquiries about their areas of expertise.
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: